Please ensure Javascript is enabled for purposes of website accessibility

Is This Really Big Pharma's Next Acquisition?

By Dave Williamson - Apr 2, 2013 at 5:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Where did all this buyout interest come from?

When shares of Optimer (NASDAQ: OPTR) jumped up in February on the news that it was seeking "strategic alternatives" -- in other words, looking for a buyer -- Motley Fool health-care analyst David Williamson warned that the company's defining drug, Dificid, has had slow sales, and finding a buyer might not be easy. However, in this video, David tells investors about an article in Bloomberg, reporting that both GlaxoSmithKline (GSK 2.20%) and AstraZeneca (AZN 2.59%) may be interested, which has shares of Optimer up 20%. David explores what Optimer has to offer that may or may not make this buyout worth the buyer's while.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$93.55 (1.58%) $1.46
GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
$44.52 (2.20%) $0.96
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$66.21 (2.59%) $1.67
Cubist Pharmaceuticals LLC Stock Quote
Cubist Pharmaceuticals LLC

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.